For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
The innovative eyedrop targets inflammation and pain following ocular surgery
Duvakitug was well tolerated and safety was consistent with the induction study
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
HCG clinicians contributing to one of the largest bodies of oncology research from India
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
